Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | JUN | P05412 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.71 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2679094 | 1.00 | RAB9A (0.71) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL31565691 | 1.00 | RAB9A (0.71) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL29514819 | 0.98 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL485947 | 0.98 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL485944 | 0.98 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL11971085 | 0.85 | MAPT (0.96) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL11971079 | 0.85 | MAPT (0.96) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL27850886 | 0.84 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| Hydrochloric Acid SCHEMBL10810828 | 0.84 | RAB9A (0.73) | RAB9AMAPTKDM4ENPC1JUN | |
| SCHEMBL5598850 | 0.83 | MAPT (1.00) | RAB9AMAPTKDM4ENPC1JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-8900796-B2 | Acid generator, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| EP-2634631-A1 | Acid generator, chemically amplified resist composition, and patterning process | Shin-Etsu Chemical Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130224657-A1 | ACID GENERATOR, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| CN-102421754-A | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO LTD | 2012-04-18 | — | — | CN | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5137638-A | Mixture of orticla isomers; cellulose tricinnamate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| US-5075009-A | Optical resolution of racemic mixtures using a cellulose tris-4-biphenyl carboxylate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
| US-5017290-A | Chromatography | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4966694-A | CELLULOSE TRI-BETA-NAPHTHOATE; OPTICAL RESOLUTIONS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0156382-B1 | SEPARATION AGENT COMPRISING ACYL-OR CARBAMOYL-SUBSTITUTED POLYSACCHARIDE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4879038-A | Separation agent comprising acyl- or carbamoyl-substituted polysaccharide | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| US-4584297-A | Pyrrolo[1,2-c]-1,3-thiazines | RHONE-POULENC SANTE (FR) | 1986-04-22 | — | — | US | disclosed |
| US-4546100-A | Pyrrolo[1,2-c]thiazoles useful as antithrombotic agents | RHONE-POULENC SANTE (FR) | 1985-10-08 | — | — | US | disclosed |
| EP-0156382-A2 | Separation agent comprising acyl-or carbamoyl-substituted polysaccharide | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4539400-A | Pyridin-3-yl substituted ortho-fused pyrrole derivatives | RHONE-POULENC SANTE (FR) | 1985-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NAPRT | RAB9A 1511/4885MAPT 422/4885KDM4E 2168/4885 |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | RAB9A 4310/4885MAPT 1476/4885KDM4E 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.